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Host defenses against Streptococcus pneumoniae depend largely on phagocytosis following opsonization by
polysaccharide-specific immunoglobulin G (IgG) antibodies and complement. Since colonization of the respi-
ratory mucosa is the first step in pneumococcal pathogenesis, mucosal immune responses may play a signif-
icant role. In addition to inducing systemic immune responses, mucosal vaccination with an effective adjuvant
has the advantage of inducing mucosal IgA antibodies. The heat-labile enterotoxin (LT) of Escherichia coli is
a well-studied mucosal adjuvant, and adjuvant activity of nontoxic LT mutants has been demonstrated for
several protein antigens. We investigated the immunogenicity of pneumococcal polysaccharide conjugate
vaccines (PNC) of serotypes 1 and 3 in mice after intranasal (i.n.) immunization by using as an adjuvant the
nontoxic LT mutant LT-K63 or LT-R72, which has minimal residual toxicity. Pneumococcal serotype-specific
antibodies were measured in serum (IgM, IgG, and IgA) and saliva (IgA), and vaccine-induced protection was
evaluated by i.n. challenge with virulent pneumococci of the homologous serotype. When administered with LT
mutants, i.n. immunization with both conjugates induced systemic and mucosal immune responses, and serum
IgG antibody levels were significantly higher than after subcutaneous immunization. All mice immunized i.n.
with PNC-1 and LT mutants were protected against bacteremia and cleared the pneumococci from the lung
24 h after i.n. challenge; pneumococcal density correlated significantly with serum IgG antibody levels.
Similarly, the survival of mice immunized i.n. with PNC-3 and LT mutants was significantly prolonged. These
results demonstrate that i.n. vaccination with PNC and potent adjuvants can protect mice against invasive and
lethal pneumococcal infections, indicating that mucosal vaccination with PNC may be an alternative vaccina-
tion strategy for humans.
Streptococcus pneumoniae is a major pathogen which enters
the body through the respiratory mucosa and may cause seri-
ous infections such as meningitis, pneumonia, and bacteremia
(36), especially in elderly people and in young children. It is
also a major cause of the childhood mucosal infection otitis
media (2, 14). The pneumococcus is encapsulated with poly-
saccharides (PS), which are the main virulence factors (39) and
protect the bacteria from host defense mechanisms, particu-
larly phagocytosis following opsonization by PS-specific anti-
bodies and complement (25, 37).
The PS, which are poorly immunogenic in young children
(20), are classified as type 2 T-cell-independent antigens. B cell
activation results in immunoglobulin M (IgM) production but
limited class switching, no affinity maturation, and little, if any,
development of memory cells (24). By conjugation of PS to
various proteins, their immunogenicity may be increased, prob-
ably by recruitment of T-cell help through linked recognition
(11, 19, 27, 32).
Currently, most licensed vaccines are administered paren-
terally and show good efficacy in protection against various
pathogens. Pneumococcal diseases can be prevented in adults
by the parenteral administration of plain PS vaccines (31), and
experimental pneumococcal polysaccharide-protein conjugate
vaccines (PNC) are immunogenic in infants (1, 5, 18, 33).
Recently, 100% efficacy against invasive pneumococcal infec-
tions in infants was reported (3) and results from efficacy trials
for acute otitis media are expected soon (10a).
Mucosal immune responses against pneumococci may be
induced by mucosal vaccination, which may have additional
benefits provided that it also induces sufficient systemic im-
mune response and generates immunological memory. It is
assumed that secretory IgA at mucosal surfaces inhibits the
adherence and invasion of mucosal pathogens and neutralizes
virulence factors (23, 35). However, mucosal vaccination has
not been adequately exploited, partly due to lack of mucosal
adjuvants acceptable for human use. Cholera toxin (CT) from
Vibrio cholerae and heat-labile enterotoxin (LT) of Escherichia
coli are strong mucosal adjuvants capable of enhancing the
immune response to mucosally coadministrated antigens (4,
10, 21). The toxicity of these proteins has prevented their use
in humans, but recently, mutants of LT and CT with no or low
toxic activity have been constructed by site-directed mutagen-
esis, and adjuvanticity of the LT mutants LT-K63 (nontoxic)
and LT-R72 (reduced toxicity) has been demonstrated for sev-
eral protein antigens (6–9, 13, 15, 26).
In this study, immune responses elicited by two serotypes of
PNC after intranasal (i.n.) administration with LT-K63 and
LT-R72 as adjuvants were investigated. Furthermore, vaccine-
induced protection was evaluated by i.n. challenge with viru-
lent pneumococci of the homologous serotype (30).
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MATERIALS AND METHODS
Mice. Outbred female NMRI mice, 6 to 8 weeks old, were obtained from the
Institute of Experimental Pathology at Keldur, Reykjavı´k, Iceland. The animals
were kept in cages with free access to commercial pelleted food and water.
Vaccines and adjuvants. Experimental PNC were provided by Pasteur
Me´rieux Connaught, Marcy l’Etoile, France. Serotype 1 PS was conjugated to
tetanus toxoid (PNC-1) and serotype 3 PS was conjugated to diphtheria toxoid
(PNC-3). Pure pneumococcal polysaccharides (PPS) were purchased from the
American Type Culture Collection (ATCC) (Manassas, Va.). For i.n. immuni-
zation, PNC or PPS were diluted in saline or mixed with the LT mutant LT-K63
(6, 7) or LT-R72 (15), provided by the Immunobiology Research Institute Siena,
Siena, Italy. Five micrograms of LT mutant per mouse was used.
Immunization. Mice were lightly sedated by subcutaneous (s.c.) injection of
Hypnorm (Janssen Pharmaceutica, Beerse, Belgium). This treatment keeps the
mice conscious, which minimizes the possibility of antigen delivery into the lung
during i.n. immunization. Eight to 10 mice per group were each immunized with
0.5 or 2.0 mg of PNC or PPS. For i.n. immunization, two doses of 10-ml vaccine
solution was slowly delivered into the nares, with 30 min between each dose. For
s.c. immunization, a 500-ml vaccine solution was injected in the scapular girdle
region. All groups were boosted with the same dose and route 2 weeks after
primary immunization. Unimmunized mice were used as controls.
Blood and saliva sampling. The mice were bled from the retro-orbital sinus 15
days after boosting and the serum was isolated and stored at 270°C. Saliva was
collected from each mouse by the insertion of absorbent sticks (Polyfiltronics
Inc., Rockland, Maine) into the mouth. After 5 min, the sticks were transferred
to phosphate-buffered saline (PBS) containing 10.0 mg of protease inhibitor
(aprotinin; Sigma Chemical Co., St. Louis, Mo.) per ml to prevent the proteolysis
of antibodies. The dissolved saliva samples for each group were pooled and
stored at 270°C.
Antibody measurements. Specific antibodies (IgM, IgG, and IgA) to pneumo-
coccal polysaccharides were determined by enzyme-linked immunosorbent assay
(ELISA) designed according to the standardized ELISA protocol (3a) with a few
modifications. Microtiter plates (MaxiSorp; Nunc AS, Roskilde, Denmark) were
coated with 10 mg of PS serotype 1 and PS serotype 3 (ATCC) per ml of PBS and
incubated for 5 h at 37°C. For the neutralization of antibodies to cell wall PS
(Statens Serum Institute, Copenhagen, Denmark), serum samples and standards
were diluted 1:50 in PBS with 0.05% Tween 20 (Sigma) and incubated in 500 mg
of cell wall PS per ml for 30 min at room temperature. The neutralized sera were
serially diluted and incubated in PPS-coated microtiter plates at room temper-
ature for 2 h. For the detection of bound antibodies, horseradish peroxidase-
conjugated goat anti-mouse IgG (Caltag Laboratories, Burlingame, Calif.), IgM,
or IgA (Sera-Lab, Crawley Down, Sussex, United Kingdom) was diluted 1:5,000
in PBS-Tween and incubated for 2 h at room temperature. For development,
3,39,5,59-tetramethylbenzidine peroxidase (Kirkegaard & Perry Laboratories,
Gaithersburg, Md.) was incubated for 10 min according to the manufacturer’s
instructions, and the reaction was stopped by addition of 0.18 M H2SO4. Absor-
bance was measured at an optical density of 450 nm in an ELISA spectropho-
tometer (Titertek Multiscan Plus MK II; Flow Laboratories, Irvine, United
Kingdom). Reference serum obtained from Pasteur Me´rieux Connaught was
included on each microtiter plate for calculation of the titers expressed in ELISA
units (EU) per milliliter. The titers of the reference sera (in ELISA units per
milliliter) corresponded to the inverse of the serum dilution, giving an optical
density of 1.0.
The assays were performed at room temperature and PBS-Tween was used for
dilutions and washing. One-hundred-microliter volumes were used in all incu-
bation steps with three washings between each step. All sera were tested in
duplicate.
Pneumococci. Serotype 1 (ATCC 6301) and serotype 3 (ATCC 6303) pneu-
mococci were maintained in tryptose broth plus 20% glycerol at 270°C. One day
before challenge, stocks were plated on blood agar (Difco Laboratories, Detroit,
Mich.) and incubated at 37°C in 5% CO2 overnight. Isolated colonies were
transferred to a brain heart infusion broth (Difco) with 10% horse serum,
cultured at 37°C to log phase for 3.5 h, and resuspended in 0.9% sterile saline.
Serial 10-fold dilutions were plated on blood agar to determine inoculum density.
Pneumococcal challenge. The challenge experiments were performed 2 days
after the mice were bled. The animals were anesthetized with pentobarbitone
sodium (50 mg/kg of body weight; Icelandic Pharmaceuticals, Reykjavı´k, Iceland)
injected intraperitoneally (i.p.). They were then challenged with 50 ml of pneu-
mococcal suspension i.n. and were allowed to aspirate it into the lungs for 10 min
(35). Blood was collected from the tail vein 24 h after challenge, plated in serial
dilutions on blood agar, and cultured at 37°C in 5% CO2 overnight. Bacteremia
was determined as the number of CFU per milliliter of blood. When the mice
were sacrificed, the lungs were removed and homogenized in 0.9% sterile saline,
and serial dilutions were plated on blood agar that included Staph/Strep selective
supplement containing nalidixic acid and colistin sulfate (Unipath Ltd., Bedford,
Hampshire, United Kingdom). Pneumococcal lung infection was determined as
the number of CFU/milliliter of lung homogenate. Depending on the first dilu-
tion used, the detection limit was 2.2 CFU/ml of lung homogenate and 1.6
CFU/ml of blood.
Statistical analysis. A nonparametric t test (a Mann-Whitney U test) was used
to compare antibody titers and numbers of CFU between groups. Correlation
was calculated with Pearson’s correlation coefficient. The Kaplan-Meier survival
test was used to compare survival rates. A P value of ,0.05 was considered to be
statistically significant.
RESULTS
Antibody responses to PNC-1. Mice were immunized i.n.
with 0.5 or 2.0 mg of PNC-1 alone or mixed with either LT-K63
or LT-R72. Administration of PNC-1 i.n. with either LT-K63
or LT-R72 elicited significantly higher antibody responses than
the s.c. route for both 0.5- and 2.0-mg doses of PNC-1 in saline
(P , 0.001). The lower dose of PNC-1 tended to elicit a higher
systemic IgG response when administered i.n. with either LT
mutant, but the difference between the two doses was not
significant (Table 1). In addition, for both doses of PNC-1, the
TABLE 1. Pneumococcal serotype-specific antibodies in serum and saliva after immunization with PPS and PNC
Vaccine
(dose [mg]) Route Adjuvant
Geometric mean titer (EU/ml)a of:
IgG IgM IgA Salivary IgAb
PNC-1 (0.5) s.c. Saline 955 (372–2,449) 149 (93–232) 90 (59–136) 3
PNC-1 (0.5) i.n. Saline 27 (6–124) 52 (36–76) 56 (26–125) 5
PNC-1 (0.5) i.n. LT-K63 9,149 (5,074–16,495) 221 (180–271) 529 (320–874) 42
PNC-1 (0.5) i.n. LT-R72 8,314 (4,675–14,785) 242 (161–365) 403 (205–792) 34
PNC-1 (2.0) s.c. Saline 519 (158–1,706) 134 (105–169) 94 (39–224) 4
PNC-1 (2.0) i.n. Saline 133 (54–312) 43 (29–63) 83 (45–155) 3
PNC-1 (2.0) i.n. LT-K63 8,638 (5,760–12,954) 209 (149–293) 235 (129–428) 12
PNC-1 (2.0) i.n. LT-R72 6,227 (3,831–10,123) 345 (273–436) 210 (133–333) 15
None (control) 5 (4–7) 34 (29–41) 69 (42–113) ND
PPS-1c (2.0) i.n. Saline 10 (7–13) 52 (35–76) 73 (34–157) ND
PPS-1 (2.0) i.n. LT-R72 25 (15–39) 50 (40–62) 96 (49–186) ND
PNC-3 (2.0) s.c. Saline 339 (233–494) 109 (76–156) 34 (17–69) 12
PNC-3 (2.0) i.n. Saline 8 (5–11) 51 (35–75) 31 (21–44) 3
PNC-3 (2.0) i.n. LT-K63 3,050 (2,034–4,573) 95 (61–148) 69 (44–108) 23
PNC-3 (2.0) i.n. LT-R72 2,546 (1,399–4,632) 94 (70–128) 68 (45–104) 31
None (control) 4 (3–5) 35 (22–57) 31 (22–44) 5
a The 95% confidence interval is given in parentheses.
b Salivary samples were pooled for each group. ND, not detectable.
c The PPS immunizations were performed in a separate experiment.
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nontoxic mutant LT-K63 tended to enhance systemic IgG re-
sponses more efficiently than LT-R72, although the differences
were not significant (P 5 0.337). Administration of PNC-1
alone via the i.n. route induced a significant systemic IgG
response compared to that in unimmunized control mice (P 5
0.016 for 0.5 mg of PNC-1 and P , 0.001 for 2.0 mg of PNC-1),
but when mixed with either LT mutant, antibody responses
were significantly enhanced (P , 0.001).
Only those mice immunized s.c. with PNC-1 in saline and i.n.
with PNC-1 and LT mutants showed significant IgM responses,
compared to unimmunized control mice (P , 0.001). Further-
more, significant systemic IgA responses were observed only
among mice immunized i.n. with PNC-1 and LT mutants (Ta-
ble 1).
Administration of PNC-1 i.n. with either LT mutant elicited
the highest mucosal IgA responses (Table 1). Furthermore,
salivary IgA levels were higher in pooled saliva of mice immu-
nized i.n. with 0.5 mg than in mice given 2.0 mg of PNC-1. Mice
immunized s.c. or i.n. with PNC-1 in saline rarely had detect-
able salivary IgA levels (Table 1).
In a separate experiment, we investigated the immunogenic-
ity of pure serotype 1 PPS (PPS-1) when administered i.n. to
two groups of mice, either with LT-R72 or in saline (Table 1).
Even though a significant systemic IgG response was observed
for both groups, compared to unimmunized control mice (P 5
0.005 for PPS-1 with LT-R72 and P 5 0.010 for PPS-1 alone),
the antibody levels were significantly lower than after i.n. im-
munization with PNC-1 with or without LT-R72 (P , 0.001 for
both groups). Neither mucosal nor significant systemic IgA was
detectable in these immunized mice.
Antibody responses to PNC-3. Mice were immunized with
2.0 mg of PNC-3 in one of three ways: i.n., i.n. with LT mutants,
or s.c. in saline. Significant serum IgG responses were observed
in mice immunized i.n. with PNC-3 with either LT mutant or
s.c. in saline, compared to the unimmunized group (P , 0.001
for all groups), but no response was observed after i.n. admin-
istration of PNC-3 in saline (P 5 0.141; Table 1). In addition,
i.n. immunization with PNC-3 mixed with either LT mutant
elicited significantly higher serum IgG levels than s.c. immu-
nization with PNC-3 in saline (P , 0.001).
Only those mice immunized i.n. with PNC-3 and either LT
mutant had significant IgA levels in serum, compared to un-
immunized control mice (P 5 0.020 for PNC-3 mixed with
LT-K63 and P 5 0.005 for PNC-3 mixed with LT-R72).
Salivary IgA levels were slightly higher in mice immunized
i.n. with PNC-3 and LT mutants than in unimmunized control
mice (Table 1) but hardly detectable in mice immunized s.c. or
i.n. with PNC-3 in saline.
Protection against pneumococcal infections caused by sero-
type 1. To evaluate vaccine-induced protection against pneu-
mococcal bacteremia and pulmonary infection caused by sero-
type 1 pneumococci, immunized mice were challenged i.n. with
106 CFU of serotype 1 pneumococci suspended in 50 ml of
saline 2 weeks after booster vaccination. Serotype 1 pneumo-
cocci were very virulent and caused severe bacteremia (mean,
;105 CFU/ml of blood) and lung infection (mean, ;107 CFU/
ml of lung homogenate) in unimmunized control mice 24 h
after i.n. challenge (Fig. 1).
All mice immunized i.n. with either 0.5 or 2 mg of PNC-1
with LT mutants were protected from pneumococcal bactere-
mia 24 h after challenge (Fig. 1A). In addition, 100% protec-
tion was observed in mice immunized s.c. with PNC-1 in saline.
Of the mice immunized i.n. with PNC-1 alone, only 3 of 16 had
detectable pneumococci in the blood, and all 3 had received 0.5
mg of PNC-1 (Fig. 1A). The level of bacteremia at 24 h was
inversely related to serotype 1-specific IgG (r 5 20.310; P 5
0.006) and IgA (r 5 20.228; P 5 0.046) in serum; bacteremia
was not detected in mice with .20 EU of serum IgG/ml (data
not shown).
Immunization i.n. with PNC-1 and LT-K63 or LT-R72 con-
ferred 100% clearance of lung infection caused by serotype 1
pneumococci (Fig. 1B). Of the mice immunized i.n. with
FIG. 1. Pneumococcal density (log CFU) in blood (A) and lungs (B) 24 h
after i.n. challenge with serotype 1 pneumococci. Each mouse is represented by
one symbol, and dotted lines indicate detection limits for CFU. The mode of
immunization is indicated on the x axis (the labels apply to both panels A and B).
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PNC-1 in saline, only 2 of 8 mice receiving 0.5 mg of PNC-1 and
4 of 8 receiving 2.0 mg of PNC-1 were protected from lung
infection, whereas 1 of 8 in each group immunized s.c. had
detectable pneumococci in the lungs. The pneumococcal den-
sity in the lungs correlated significantly with serotype 1-specific
IgG (Fig. 2) and IgA antibody levels in serum (r 5 20.428, P ,
0.001 for IgG; r 5 20.285, P 5 0.012 for IgA), and no pneu-
mococci were detectable in lungs of mice with .300 EU of
serum IgG/ml.
A total of 6 of 10 mice immunized i.n. with pure PPS-1 and
LT-R72 were protected against bacteremia, but only 1 of 10
mice immunized i.n. with PPS-1 alone were protected. Only 3
of 10 mice immunized i.n. with PPS-1 and LT-R72 were pro-
tected from lung infection; the lungs of all mice immunized i.n.
with PPS-1 in saline were heavily infected (data not shown).
Protection against pneumococcal infections caused by sero-
type 3. Immunized mice were challenged i.n. with 104 CFU of
serotype 3 pneumococci, and survival was recorded over 10
days when the experiment was terminated (Fig. 3). The chal-
lenge killed 80% of both unimmunized control mice and mice
immunized i.n. with PNC-3 alone, but among mice immunized
s.c. with PNC-3 in saline, survival was significantly prolonged,
and 90% of these mice were protected at day 10 (P 5 0.006).
Immunization i.n. with PNC-3 mixed with LT mutants induced
significantly prolonged survival, and 100% of the mice receiv-
ing LT-K63 (P , 0.001) and 90% of the mice receiving LT-R72
(P 5 0.006) were still alive and looked healthy at day 10 (Fig. 3).
DISCUSSION
PNC are now in phase II and phase III clinical trials, and
safety and immunogenicity has been demonstrated in infants
vaccinated parenterally (1, 5, 18, 33). Antibodies elicited in
infants mediate opsonophagocytosis in vitro (17, 33, 38) and
protect mice against invasive infections if passively adminis-
tered i.p. before i.n. challenge with virulent pneumococci (29).
Since the mucosal epithelium of the nasopharynx is the pri-
mary site of pneumococcal colonization (36), i.n. vaccination
may be an alternative approach to current strategies, mainly
because it may induce both mucosal and systemic immune
responses. In addition, such vaccination is painless and easy to
perform, which should favor these strategies for the immuni-
zation of infants and children. Most antigens are poor mucosal
immunogens, partly because they lack receptor-binding prop-
erties to epithelial cells in the mucosa. Exceptions are proteins
such as CT and E. coli LT (34, 40). These toxins are also
exceptionally powerful mucosal adjuvants, inducing antibody
production to mucosally coadministrated unlinked antigens
(4, 10, 21). Both LT and CT are ADP-ribosylating holotoxins
composed of an enzymatically active A subunit and a pentam-
eric, nontoxic B subunit which binds with high affinity to GM1
ganglioside cell surface receptors and promotes the entry of
the A unit into the cell (34). Reports have suggested that the
toxic A subunit is necessary for the adjuvant activity of CT and
LT (22), but recently, several mutants have been constructed
which have reduced or which totally lack ADP-ribosylating
activity while the useful immunological properties are main-
tained (6–9, 13, 15, 26). The adjuvant activity of the nontoxic
LT-K63, with a serine-to-lysine change at position 63, has been
demonstrated for bystander antigens (6, 7), and another LT
mutant, LT-R72, which contains an alanine-to-arginine substi-
tution in position 72 in the A subunit, showed greatly reduced
enzymatic activity compared to wild-type LT while adjuvant
activity was maintained (15).
In this study, we demonstrated that i.n. immunization with
PNC-1 and PNC-3, with LT-K63 and LT-R72 as adjuvants,
elicits significant immune responses in mice. Furthermore, vac-
cine-induced protection against invasive infections caused by
homologous pneumococcal serotypes was established. Immu-
nization i.n. with both PNC-1 and PNC-3 with LT mutants was
more efficient than immunization with PNC in saline by the s.c.
route, in terms of both immunogenicity and protection. Sys-
temic PPS-specific IgG antibodies are known to protect against
FIG. 2. Relationship between pneumococcal density in lung (as log CFU)
24 h after i.n. challenge and serotype 1-specific IgG antibody levels in serum (in
ELISA units/milliliter). Each symbol represents one mouse, and the horizontal
dotted line indicates the detection limit for CFU.
FIG. 3. Survival of mice (n 5 10 per group) after i.n. challenge with serotype
3 pneumococci.
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invasive pneumococcal infections (39), and we found that very
low antibody levels were sufficient to prevent bacteremia and
that clearance of serotype 1 pneumococci from the lungs was
significantly related to PPS-specific serum IgG levels (Fig. 2).
Immunization with PPS-1 and LT-R72 i.n. elicited a systemic
IgG response, but the levels were significantly lower than the
responses elicited by PNC-1 and were insufficient to clear the
infection (data not shown).
Interestingly, both PNC-1 and PNC-3 tended to induce
higher systemic antibody responses when mixed with the non-
toxic mutant LT-K63 than with LT-R72, which appears to
contradict results obtained with these two LT mutants when
adjuvant activities for protein antigens were compared (15). A
similar trend was observed in antibody response to PNC of
other serotypes (unpublished data). Furthermore, the lower
dose of PNC-1 seemed to elicit higher systemic and mucosal
antibody responses than did the higher dose when adminis-
tered i.n. with either LT mutant. It has already been demon-
strated that PNC-1 and PNC-3 induce serum IgG antibodies in
mice when administered i.n. in a glyceride-based adjuvant (16).
However, the dose of PNC-1 required to elicit a 100% protec-
tive immune response was higher (16) than when the conju-
gates were administered with LT mutants, which suggests that
the LT mutants may be more feasible adjuvants for i.n. immu-
nization with multivalent PNCs.
Secretory IgA is considered to be an important immunolog-
ical first-line defense at mucosal surfaces, and it is assumed
that it inhibits adherence and invasion of mucosal pathogens
and neutralizes virulence enzymes and toxins (35). In addition,
it has been postulated that there is a simple transudation of
serum IgG on mucosal surfaces (28). When mice were immu-
nized i.n. with pneumococcal surface protein A (PspA) with
the B subunit of CT as an adjuvant (41), significant PspA-
specific levels of IgA antibodies were detected in saliva. In
addition, the mice were protected against long-lasting carriage
of S. pneumoniae, which indicates a role of mucosal IgA anti-
bodies in the protection of mucosal surfaces. In contrast, i.n.
immunization with PPS-6B conjugated to tetanus toxoid in-
duced a marginal salivary IgA response, but significant serum
IgG levels were observed (41). Furthermore, oral immuniza-
tion of mice with PPS-23 conjugated to the outer membrane
protein complex of Neisseria meningitides in enterocoated mi-
croparticles was found to be insufficient for the induction of
salivary IgA (12). However, oral immunization may induce
mucosal immune responses in the presence of a mucosal ad-
juvant such as CT (21). In the present study, IgA antibodies
were detectable in saliva only after i.n. administration of PNC
with LT mutants. The salivary IgA measurements were per-
formed on saliva samples which were pooled for each group,
and thus it was not possible to evaluate the relationship be-
tween salivary IgA levels and protection against pneumococcal
infections. Serum IgA may be considered a surrogate for mu-
cosal IgA response. A weak negative correlation was found
between serum IgA levels and pneumococcal density in the
lungs and blood, indicating that mucosal IgA may be of im-
portance in clearing the pneumococci. However, this may also
be secondary to the correlation between IgG and IgA in serum
(r 5 0.246; P 5 0.032).
We have demonstrated that mucosal vaccination with PNC
and nontoxic LT mutants elicits mucosal as well as systemic
immune responses in mice and protects against invasive pneu-
mococcal infections. The results indicate that this vaccination
strategy may be an alternative approach for preventing pneu-
mococcal diseases and encourage its evaluation in humans.
ACKNOWLEDGMENTS
We acknowledge the valuable scientific advice of Giuseppe Del
Giudice at the Immunobiology Research Institute Siena, Siena, Italy,
and Bernard Danve at Pasteur Me´rieux Connaught, Marcy l’Etoile,
France, and the excellent assistance of Sonja Vilhja´lmsdo´ttir and Si-
gru´n Marı´a Bjarnado´ttir. We appreciate the facilities provided by the
Department of Microbiology, National University Hospital, Reykjavı´k,
Iceland.
This work was supported by the Research Fund of the University of
Iceland and Pasteur Me´rieux Connaught, Marcy l’Etoile, France.
REFERENCES
1. Åhman, H., H. Ka¨yhty, P. Tamminen, A. Vuorela, F. Malinoski, and J.
Eskola. 1996. Pentavalent pneumococcal oligosaccharide conjugate vaccine
PncCRM is well-tolerated and able to induce an antibody response in in-
fants. Pediatr. Infect. Dis. J. 15:134–139.
2. Austrian, R., and J. Gold. 1981. Some observations on the pneumococcus
and on the current status of pneumococcal disease and its prevention. Rev.
Infect. Dis. 3(Suppl.):S1–17.
3. Black, S., H. Shinefield, and P. Ray. 1998. Efficacy of heptavalent conjugate
pneumococcal vaccine (Wyeth-Lederle) in 37,000 infants and children: re-
sults of the Northern California Kaiser Permanente Trial, p. 18. Presented at
the Pneumococcal Vaccines for the World 1998 Conference, Washington
D.C., 12 to 14 October 1998.
3a.Centers for Disease Control and Prevention. 1996. WHO Pneumococcal
ELISA Workshop, Atlanta, Ga., 15 to 17 May 1996.
4. Clements, J. D., N. M. Hartzog, and F. L. Lyon. 1988. Adjuvant activity of
Escherichia coli heat-labile enterotoxin and effect on the induction of oral
tolerance in mice to unrelated protein antigens. Vaccine 6:269–277.
5. Dagan, R., R. Melamed, O. Zamir, and O. Leroy. 1997. Safety and immu-
nogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and
23F polysaccharide conjugated to either tetanus toxoid or diphtheria toxoid
in young infants and their boosterability by naive polysaccharide antigens.
Pediatr. Infect. Dis. J. 16:1053–1059.
6. Di Tommaso, A., G. Saletti, M. Pizza, R. Rappuoli, G. Dougan, S. Abrignani,
G. Douce, and M. T. De Magistris. 1996. Induction of antigen-specific anti-
bodies in vaginal secretions by using a nontoxic mutant of heat-labile en-
terotoxin as a mucosal adjuvant. Infect. Immun. 64:974–979.
7. Douce, G., M. Fontana, M. Pizza, R. Rappuoli, and G. Dougan. 1997. Intra-
nasal immunogenicity and adjuvanticity of site-directed mutant derivatives of
cholera toxin. Infect. Immun. 65:2821–2828.
8. Douce, G., M. M. Giuliani, V. Gianelli, M. Pizza, R. Rappuoli, and G.
Dougan. 1998. Mucosal immunogenicity of genetically detoxified derivatives
of heat labile toxin from Escherichia coli. Vaccine 16:1065–1073.
9. Douce, G., C. Turcotte, I. Cropley, M. Roberts, M. Pizza, M. Domenighini,
R. Rappuoli, and G. Dougan. 1995. Mutants of Escherichia coli heat-labile
toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adju-
vants. Proc. Natl. Acad. Sci. USA 92:1644–1648.
10. Elson, C. J., and W. Ealding. 1984. Generalized systemic and mucosal im-
munity in mice after mucosal stimulation with cholera toxin. J. Immunol.
132:2736–2741.
10a.Eskola, J. Personal communication.
11. Eskola, J., and H. Ka¨thy. 1994. New vaccines for prevention of pneumococ-
cal infections. Trends Mol. Med. 27:53–56.
12. Flanagan, M. P., and J. G. Michael. 1999. Oral immunization with a Strep-
tococcal pneumoniae polysaccharide conjugate vaccine in enterocoated mi-
croparticles induces serum antibodies against type specific polysaccharides.
Vaccine 17:72–81.
13. Fontana, M. R., R. Manetti, V. Giannelli, C. Magagnoli, A. Marchini, R.
Olivieri, M. Domenighini, R. Rappuoli, and M. Pizza. 1995. Construction of
nontoxic derivatives of cholera toxin and characterization of the immuno-
logical response against the A subunit. Infect. Immun. 63:2356–2360.
14. Giebink, G. S. 1985. Preventing pneumococcal diseases in children: recom-
endations for using pneumococcal vaccine. Pediatr. Infect. Dis. J. 4:343–348.
15. Giuliani, M. M., G. D. Giudice, V. Gianelli, G. Dougan, G. Douce, R.
Rappuoli, and M. Pizza. 1998. Mucosal adjuvanticity and immunogenicity of
LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with par-
tial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1123–
1132.
16. Jakobsen, H., E. Saeland, S. Gizurarson, D. Schulz, and I. Jo´nsdo´ttir. 1999.
Intranasal immunization with pneumococcal polysaccharide conjugate vac-
cines protects mice against invasive pneumococcal infections. Infect. Immun.
67:4128–4133.
17. Jonsdottir, I., S. T. Sigurdardottir, G. Vidarsson, G. Ingolfsdottir, T. Gud-
nason, K. Davidsdottir, S. Kjartansson, and O. Leroy. 1997. Functional
activity of antibodies elicited by octavalent pneumococcal polysaccharide
conjugate vaccines, PncT and PncD, abstr. G-90, p. 209. In Abstracts of the
37th Interscience Conference on Antimicrobial Agents and Chemotherapy.
American Society for Microbiology, Washington, D.C.
18. Ka¨yhty, H., H. Aahman, P. R. Ronnberg, R. Tillikainen, and J. Eskola. 1995.
5896 JAKOBSEN ET AL. INFECT. IMMUN.
Pneumococcal polysaccharide-meningococcal outer membrane protein com-
plex conjugate vaccine is immunogenic in infants and children. J. Infect. Dis.
172:1273–1278.
19. Ka¨yhty, H., and J. Eskola. 1996. New vaccines for the prevention of pneu-
mococcal infections. Emerg. Infect. Dis. 2:289–298.
20. Leinonen, M., A. Sakkinen, and R. Kalliokoski. 1986. Antibody response to
14-valent pneumococcal capsular polysaccharide vaccine in pre-school age
children. Pediatr. Infect. Dis. 5:39–44.
21. Lycke, N., and J. Holmgren. 1986. Strong adjuvant properties of cholera
toxin on gut mucosal immune responses to orally presented antigens. Im-
munology 59:301–308.
22. Lycke, N., T. Tsuji, and J. Holmgren. 1992. The adjuvant effect of Vibrio
cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-
ribosyltransferase activity. Eur. J. Immunol. 22:2277–2281.
23. Mestecky, J., S. M. Michalek, Z. Moldoveanu, and M. W. Russel. 1997.
Routes of immunization and antigen delivery systems for optimal mucosal
immune responses in humans. Behring Inst. Mitt. 98:33–43.
24. Mond, J. J., A. Lees, and C. M. Snapper. 1995. T cell-independent antigens
type 2. Annu. Rev. Immunol. 13:655–692.
25. Musher, D. M., A. J. Chapman, A. Goree, S. Jonsson, D. E. Briles, and E.
Baughn. 1986. Natural and vaccine-related immunity to Streptococcus pneu-
moniae. J. Infect. Dis. 154:245–256.
26. Pizza, M., M. Domenighini, W. Hol, V. Gianelli, M. R. Fontana, M. M.
Giuliani, C. Magagnoli, S. Peppoloni, R. Manetti, and R. Rappuoli. 1994.
Probing the structure-activity relationship of Escherichia coli LT-A by site-
directed mutagenesis. Mol. Microbiol. 14:51–60.
27. Robbins, J. B., and R. Schneerson. 1990. Polysaccharide-protein conjugates:
a new generation of vaccines. J. Infect. Dis. 161:821–832.
28. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Perspective: hypothesis:
serum IgG antibody is sufficient to confer protection against infectious dis-
eases by inactivating the inoculum. J. Infect. Dis. 171:1387–1398.
29. Sæland, E., H. Jakobsen, G. Ingolfsdottir, S. T. Sigurdardottir, and I.
Jonsdottir. 1998. Pneumococcal polysaccharide conjugate vaccines elicit anti-
bodies in infants that are protective in vivo in mice, abstr. 115. Presented at
the International Symposium on Pneumococci and Pneumococcal Diseases,
Elsinore, Denmark, 13 to 17 June 1998.
30. Sæland, E., G. Vidarsson, and I. Jonsdottir. Pneumococcal infection model
in mice for analysis of protective human antibodies. Submitted for publica-
tion.
31. Shapiro, E. D., A. T. Berg, R. Austrian, D. Schroeder, V. Parcells, and A.
Margolis. 1991. The protective efficacy of polyvalent pneumococcal polysac-
charide vaccine. N. Engl. J. Med. 325:1453–1460.
32. Siber, G. R. 1994. Pneumococcal disease: prospects for a new generation of
vaccines. Science 265:1385–1387.
33. Sigurdardottir, S. T., G. Vidarsson, T. Gudnason, S. Kjartansson, K. G.
Kristinsson, S. Jonsson, H. Valdimarsson, G. Schiffman, R. Schneerson, and
I. Jonsdottir. 1997. Immune responses of infants vaccinated with serotype 6B
pneumococcal polysaccharide conjugated with tetanus toxoid. Pediatr. In-
fect. Dis. J. 16:667–674.
34. Spangler, B. D. 1992. Structure and function of cholera toxin and the related
Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 56:622–647.
35. Steinmetz, I. 1997. Comparative in vivo analysis of IgA- and IgG-mediated
mucosal defense against bacterial pathogens. Behring Inst. Mitt. 98:53–55.
36. Toumanen, E. I., R. Austrian, and H. R. Masure. 1995. Pathogenesis of
pneumococcal infection. N. Engl. J. Med. 332:1280–1284.
37. Vidarsson, G., I. Jonsdottir, S. Jonsson, and H. Valdimarsson. 1994. Opso-
nization and antibodies to capsular and cell wall polysaccharides of Strepto-
coccus pneumoniae. J. Infect. Dis. 170:592–599.
38. Vidarsson, G., S. T. Sigurdardottir, T. Gudnason, S. Kjartansson, K. G.
Kristinsson, G. Ingolfsdottir, S. Jonsson, H. Valdimarsson, G. Schiffman, R.
Schneerson, and I. Jonsdottir. 1998. Isotypes and opsonophagocytosis of
pneumococcus type 6B antibodies elicited in infants and adults by experi-
mental pneumococcus type 6B-tetanus toxoid vaccine. Infect. Immun. 66:
2866–2870.
39. Watson, D. A., D. M. Musher, and J. Verhoef. 1995. Pneumococcal virulence
factors and host immune responses to them. Eur. J. Clin. Microbiol. Infect.
Dis. 14:479–490.
40. Williams, N. A., T. R. Hirst, and T. O. Nashar. 1999. Immune modulation by
the cholera-like enterotoxins: from adjuvant to therapeutic. Immunol. Today
20:95–101.
41. Wu, H., M. H. Nahm, Y. Guo, M. W. Russel, and D. E. Briles. 1997.
Intranasal immunization of mice with PspA (pneumococcal surface protein
A) can prevent intranasal carriage, pulmonary infection and sepsis with
Streptococcus pneumoniae. J. Infect. Dis. 175:839–846.
Editor: V. A. Fischetti
VOL. 67, 1999 MUCOSAL IMMUNIZATION AGAINST PNEUMOCOCCAL INFECTIONS 5897
